InvestSMART

Neurotech International Limited (ASX:NTI)

ALERT: Price-sensitive ASX Announcement for NTI
Current share price for NTI : $0.014 0 (0%)+
Announcement
Release
26 Feb 2026 6:15PM
Price at Release
$0.014
Full Release
download
Summary
Neurotech International Limited reported a net loss of $696,501 for the half-year ended 31 December 2025. Throughout this period, the company made significant progress in advancing its lead broad-spectrum cannabinoid therapy, NTI164, for various paediatric neurological disorders such as Autism Spectrum Disorder. NTI164 showed clinically significant benefits in Phase II/III trials and received a Rare Pediatric Disease Designation from the FDA for Rett syndrome. The company initiated an Authorised Prescriber Program in Australia and planned further clinical studies, including a Phase III study for ASD. Neurotech's financial position was bolstered by a $4.73 million R&D tax incentive refund, contributing to their cash reserves of $6,341,734.
Key Points
  • Neurotech International Limited reported a net loss of $696,501 for the half-year ended 31 December 2025.
  • The company advanced its lead cannabinoid therapy, NTI164, for multiple paediatric neurological conditions.
  • NTI164 completed Phase II/III trials in Autism Spectrum Disorder with positive outcomes.
  • Neurotech initiated an Authorised Prescriber Program in Australia for NTI164.
  • The company received FDA Rare Pediatric Disease Designation for NTI164 in Rett syndrome.
  • A successful clinical trial could lead to market authorisation for NTI164 in the US and Australia.
  • Neurotech had a cash position of $6,341,734 as at 31 December 2025, strengthened by a $4.73 million R&D tax incentive refund.
  • The company announced collaborations and received new regulatory approvals to advance NTI164.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.